NEW YORK (GenomeWeb News) - Perlegen Sciences said this week that it has licensed certain breast cancer biomarkers from Cambridge Enterprise Limited, the commercial arm of Cambridge University, and plans to commercialize the markers as a diagnostic test.
 
The agreement stems from a large-scale breast cancer study Perlegen, Cambridge, and Cancer Research UK began in 2005 that genotyped more than 50,000 women.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.